Technology | October 11, 2013

AccessClosure Announces Distribution Agreement for Flash Ostial System

Treatment of ostial disease expands AccessClosure’s portfolio

cath lab stents ostial accessclosure flash system dual balloon angioplasty

October 11, 2013 — AccessClosure Inc. announced an exclusive agreement with Ostial Corp. to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The system is designed to help overcome the challenges of aorto-ostial stenting and complements the Mynx product family of vascular closure devices.

Ostial lesions are a challenging area for treatment.   According to Richard Kovach, M.D., chair, interventional cardiology and director, cardiac catheterization laboratory at Deborah Heart and Lung Center, in Browns Mills, N.J., “The dual balloon design of the Flash Ostial System is an exciting treatment option for ostial disease.  Flash conforms to the ostium to enable excellent stent apposition, which is important for coverage of the disease and for preserving reaccess to the treated vessel.”  Kovach has been using the Flash Ostial System in his practice for the past year.    

AccessClosure showcased its portfolio of devices at the Vascular Interventional Advances 2013 (VIVA) in Las Vegas.

For more information: www.accessclosure.com, www.ostial.com


Related Content

News | Stents

July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and ...

Home July 05, 2022
Home
News | Stents

June 2, 2022 — According to the U.S. Food and Drug Administration (FDA), Atrium Medical Corporation is recalling the ...

Home June 02, 2022
Home
News | Stents

May 13, 2022 — Vascular diseases are public enemy number one: the leading killers worldwide, accounting for nearly a ...

Home May 13, 2022
Home
News | Stents

April 6, 2022 – Narrowed arteries can restrict blood flow to the heart. One treatment is inserting a stent — a small ...

Home April 06, 2022
Home
News | Stents

November 9, 2021 — Results from SUGAR trial, a randomized, controlled, multicenter trial conducted exclusively in ...

Home November 09, 2021
Home
News | Stents

June 30, 2021 — Abbott announced its Xience family of drug-eluting coronary stents received U.S. Food and Drug ...

Home June 30, 2021
Home
News | Stents

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

Home April 14, 2021
Home
News | Stents

April 6, 2021 — Abbott today announced its Xience stent has received CE mark in Europe for shorter duration of dual anti ...

Home April 06, 2021
Home
News | Stents

December 21, 2020 – A proposed ASTM International standard will answer the need for a standardized test method that ...

Home December 21, 2020
Home
News | Stents

November 24, 2020 — One-year results off the PIONEER III study comparing the safety and efficacy of the Supreme HT ...

Home November 24, 2020
Home
Subscribe Now